Cingulate (CING)
Cingulate Inc., a biopharmaceutical company, develops pharmaceutical products using its drug delivery platform technology for the treatment of attention deficit...
- Open
- 5.280
- High
- 5.350
- Low
- 5.140
- Prev. Close
- 5.250
- Volume
- 91.29K
- Turnover
- 478.18K
- Avg Price
- 5.238
- Bid/Ask Ratio
- 60.00%
- Amplitude
- 4.00%
- 52wk High
- 11.890
- Volume Ratio
- 0.80
- Turnover Ratio
- 0.77%
Cingulate Analyst Rating
View moreForecast & Rating
Jul 30, 2026Price forecast
$23.00342.31%
Forecast & RatingStrong buy
4analysts
- Strong buy75.00%
- Buy25.00%
- Hold0.00%
- Sell0.00%
- Strong sell0.00%
News
- Unusual Whales · 21 hours ago
Cingulate Publishes Peer-Reviewed Data Demonstrating CTx-1301’s Differentiated Pharmacokinetic Profile
- PUBT · 21 hours ago
Cingulate publishes peer-reviewed pharmacokinetic study of ADHD candidate CTx-1301 in CNS Drugs
- PUBT · Jul 30 at 07:33 AM
Cingulate Phase 3 ADHD trial results for CTx-1301 published in Journal of Child and Adolescent Psychopharmacology
- PUBT · Jul 23 at 03:27 PM
Cingulate eliminates chief legal officer role, Nilay Patel to depart Aug. 3
- Tip Ranks · Jul 15 at 03:06 AM
Cingulate enhances equity plan and updates board leadership
- Tip Ranks · Jul 2 at 08:30 AM
Cingulate Inc Added to Broad Russell 3000E Index
